DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation2 articles · 2 high

21 CFR 211.68

Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.68: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under 21 CFR 211.68?
2 DSRV articles cite 21 CFR 211.68. Enforcement cases behind them: Anthropic Managed Agents (July 2026 public beta) read against Purolea Cosmetics Lab FDA Warning Letter (April 2026); FDA Warning Letter 707857 to Shiva Analyticals Private Limited, July 23, 2025, read alongside warning letters to Global Calcium Pvt. Limited (January 16, 2025), Landy International (June 12, 2024), and A. Nelson and Co. Ltd. (February 12, 2026). Inspection exposure across them: 2 high.
What does DSRV recommend for 21 CFR 211.68?
From the newest article (Your Next 483 Observation Is Running on a Timer): Defining the QU boundary, validation basis, and change-control wrapper around autonomous agent actions is the firm's job, not the vendor's — settle it before a scheduled agent fires. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 6 min readHigh exposurecited as a tag

    Your Next 483 Observation Is Running on a Timer

    Anthropic's July 2026 Managed Agents release ships scheduled autonomous runs and authenticated enterprise access. Pharma quality teams that have approved these capabilities without a QU review checkpoint built into the workflow architecture are building toward a Purolea-pattern inspection finding.

    Case
    Anthropic Managed Agents (July 2026 public beta) read against Purolea Cosmetics Lab FDA Warning Letter (April 2026)
    DSRV take
    Defining the QU boundary, validation basis, and change-control wrapper around autonomous agent actions is the firm's job, not the vendor's — settle it before a scheduled agent fires.
  2. 5 min readHigh exposure

    What FDA's Data Integrity Remediation Demands Actually Reveal

    When FDA's warning letters require independent assessments, patient-risk analyses, and global CAPA strategies, the agency is not just describing consequences. It is disclosing the standards it expected to find before the inspection started.

    Case
    FDA Warning Letter 707857 to Shiva Analyticals Private Limited, July 23, 2025, read alongside warning letters to Global Calcium Pvt. Limited (January 16, 2025), Landy International (June 12, 2024), and A. Nelson and Co. Ltd. (February 12, 2026).
    DSRV take
    FDA's remediation demands, read in reverse, are a published specification of baseline CGMP: enabled and reviewed audit trails, individual role-limited access, formally retained raw data, and a quality unit that surfaces data integrity anomalies before an inspector does.
Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under 21 CFR 211.68. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about 21 CFR 211.68

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.